Technology ID
TAB-3555
Mutant IDH1 Inhibitors for Anticancer Therapy
E-Numbers
E-189-2016-0
Lead Inventor
Boxer, Matthew
Lead IC
NCATS
Co-Inventors
Rohde, Jason
Pragani, Rajan
Liu, Li
Davis, Mindy
Brimacombe, Kyle
Shen, Min
Simeonov, Anton
Karavadhi, Surendra
Jadhav, Ajit
Hall, Matthew
Zhao, Wei
Fang, Yuhong
Martinez, Natalia
Wang, Xiaodong
McIver, Andrew
ICs
NCATS
FDA
Applications
Therapeutics
Therapeutic Areas
Oncology
This technology includes mutant isocitrate dehydrogenase (IDH1) inhibitors to be utilized as anticancer therapy. These potent inhibitors are aimed at lowering levels of the oncometabolite–2-hydroxyglutarate.
Commercial Applications
Anticancer agent that targets IDH1 mutations.
Licensing Contact: